SGLT2i downregulate the activin/inhibin and miR-1306-5p signaling pathways in patients with HFrEF and associated pulmonary hypertension: a prospective intervention study
Event:
ESC Congress 2025
Topic:
Treatment
Session:
Pulmonary arterial hypertension: general (3)